You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Painless, Bloodless And Safe Glucose Sensing System For The Pediatric Intensive Care Unit

    SBC: Fluorometrix Biomedical Company            Topic: NICHD

    DESCRIPTION provided by applicant Studies in the pediatric intensive care unit PICU have shown that hypoglycemia hyperglycemia as well as swings in blood glucose levels are strongly associated with higher morbidity and mortality However tight glucose control has not been proven as effective In fact hypoglycemia was found to be a real danger Thus there is a need for more careful study ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer

    SBC: ACTORIUS PHARMACEUTICALS, LLC            Topic: 100

    DESCRIPTION provided by applicant Breast cancer is the most common type of cancer in women between the ages of and and responsible for deaths annually If treated early five year survival rates for patients in the U S are between and but drop to once metastatic breast cancer has developed Thus there is a great need to develop more effective treatment strategies fo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers

    SBC: Atrin Pharmaceuticals            Topic: 103

    PROJECT SUMMARY Specific targeting of the Ataxia Telangiectasia and Rad related kinase ATR represents an emerging strategy to treat a broad spectrum of cancers most notably those that currently lack effective treatments Suppression of ATR selectively kills cells subjected to oncogenic stress alternative lengthening of telomeres ALT or loss of double strand break DSB repair mechanisms A ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 103

    ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. In vitro human model for individualized response to CFTR modulators

    SBC: Progenra, Inc            Topic: NHLBI

    DESCRIPTION provided by applicant The approval of the cystic fibrosis CF drug invocator for patients with the G D mutation validates CFTR modulators for improving clinical outcomes in CF For most CF patients with F del and other mutations however multi drug combination therapy will likely be necessary and sensitive biomarkers of augmented CFTR function in response to various agents ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Medical Food for the Management of Iron Deficiency Anemia

    SBC: CHYNA, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant We will perform a clinical study to test a novel patented medical food to manage iron deficiency anemia The project is significant because it addresses the number one nutritional disorder in the world and a health problem on the global scale that is second only to tuberculosis in cost worldwide Estimates are that approximately billion people more than ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of novel research tools and a database for mapping human mitochondrial tRNA modifications by mass spectrometry

    SBC: Ribonova Inc.            Topic: R42

    Summary In this fast track Phase I II STTR project a novel mass spectrometry method and a matched reagent kit will be developed for mapping modified nucleotides in human mitochondrial transfer RNA mt tRNA including the most abundant modification pseudouridine which hitherto has proved to be a technical challenge because it is an isomer of uridine These new research tools will be harnessed to build ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Small Molecule Inhibitors of HIV Nef Virulence Factor for Treatment of HIV AIDS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: 100

    DESCRIPTION provided by applicant While HIV AIDS can be managed with antiretroviral drugs these agents do not clear the virus and require life long administration Recently we discovered a completely new class of compounds that interfere with the HIV virulence factor called Nef This viral protein is critical to HIV replication in vivo immune escape of HIV infected cells and AIDS progre ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Magnetic levitation motor for pediatric cardiac and cardiopulmonary therapies

    SBC: ENSION Inc            Topic: NHLBI

    Abstract This Phase I STTR application proposes development of an innovative low cost magnetic levitation motor specifically designed for pediatric extracorporeal cardiac and cardiopulmonary therapies Magnetic levitation enables contact free impeller operation thereby eliminating critical areas of wear and heat generation that can contribute to hemolysis and thrombosis The extracorporeal pedia ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. SMALL MOLECULE ANTAGONISTS OF PF FOR THE TREATMENT AND PREVENTION OF HIT

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    DESCRIPTION provided by applicant We have discovered the first ever inhibitors of PF a platelet protein central to the pathophysiology of heparin induced thrombocytopenia HIT Heparin is a naturally occurring anticoagulant that prevents the formation of clots and extension of existing clots within the vasculature and major medical applications of heparin include dialysis cardiac catheteri ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government